{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}],"title":"≥ 1 Albumin-bound paclitaxel dose interruption"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"9"}]}],"title":"At least 1 Gemcitabine dose interruption"}],"denoms":[{"counts":[{"groupId":"OG000","value":"421"},{"groupId":"OG001","value":"402"}],"units":"Participants"}],"description":"The number of participants with dose interruptions experienced by participants that occurred during the treatment period. Dose interruptions are typically caused by clinically significant laboratory abnormalities and /or treatment emergent adverse events/toxicities.","groups":[{"description":"Albumin-bound paclitaxel (ABI-007)/Gemcitabine: ABI-007 125 mg/m\\^2 administered intravenously (IV) in combination with Gemcitabine 1000 mg/m\\^2 IV weekly for 3 weeks on Days 1, 8, and 15 followed by one week of rest","id":"OG000","title":"Albumin-bound Paclitaxel (ABI-007)/Gemcitabine"},{"description":"Gemcitabine 1000 mg/m\\^2 administered IV weekly for 7 weeks through Day 43 followed by a week of rest (Cycle 1), followed by cycles of weekly administration for 3 weeks on Days 1, 8, and 15 followed by a week of rest (Cycle 2 onward)","id":"OG001","title":"Gemcitabine"}],"paramType":"NUMBER","populationDescription":"Safety population, includes participants who received at least one study treatment","reportingStatus":"POSTED","timeFrame":"Maximum time on treatment was 666 days","title":"Number of Participants With Dose Interruptions","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"participants"}